Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial

Bitget2026/10/02 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Surrozen’s IND for SZN-8141, an intravitreal DME candidate combining a Wnt agonist with a VEGF antagonist.
First patient dosing in the Phase 1b/2a DUET study expected in Q4 2026.
Milestone triggers a second closing of the March 2025 private placement, expected to raise about $95.1 million in gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surrozen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020800PRIMZONEFULLFEED9838460) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial

You may also like

Crypto prices